Oral allopregnanolone compositions and methods of use
US12186327B2 · kind B2 · utility
Inventors
Key dates
| Filing date | Oct 4, 2022 |
| Grant date | Jan 7, 2025 |
| Priority date | — |
| Expiry date | Oct 4, 2042 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61P25/24
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Disclosed is a method and an oral composition for treating CNS disorders. An embodiment of the invention comprises orally administering an allopregnanolone containing composition to a subject having a CNS disorder. Exemplary CNS disorders include sleep disorders, mood disorders, dysthymic disorders, bipolar disorders, anxiety disorders, stress disorders, compulsive disorders, schizophrenia spectrum disorders, convulsive disorders, memory disorders, cognition disorders, movement disorders, personality disorders, autism spectrum disorders, substance abuse disorders, dementia, pain, traumatic brain injury (TBI), vascular disease, withdrawal syndrome, and tinnitus. The composition and methods disclosed herein exhibit effective oral absorption/bioavailability.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.